Asterias Appoints CEO
This article was originally published in Scrip
Regenerative medicine focused Asterias BioTherapeutics, Inc. has appointed Stephen L. Cartt president, CEO and a member of its board of directors. Don M. Bailey has also been appointed chair of the company's board. Cartt replaces Pedro Lichtinger, who was president, CEO and a board member since 2014. Bailey succeeds Alfred D. Kingsley who will remain on the board. Cartt started his career at ALZA Corporation where he held various R&D and commercial positions. He later served as senior director of strategic marketing at Elan Pharmaceuticals. He was also executive vice president, chief business officer and chief operating officer at Questcor. Bailey was president, CEO and on the board of Questcor and he was also board member and chair of the portfolio committee of Mallinckrodt. He is currently director, audit committee chair, and a member of the transaction committee of Biotie Therapies Corp.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.